Establishing an RNA fusions panel in soft tissue sarcoma with clinical validation
Xiaoqiang Huang1,2, Guibin Li3, Linghua Li4
1Guangzhou KingMed Center for Clinical Laboratory Co. Ltd., Guangzhou, China.
Scientific Reports
|March 17, 2023
Summary
A new RNA sequencing panel accurately identifies gene fusions in soft tissue sarcomas (STS), aiding precise diagnosis. This molecular tool improves classification when morphology is unclear.
Area of Science:
- Oncology
- Molecular Diagnostics
- Genetics
Background:
- Soft tissue sarcoma (STS) diagnosis is challenging due to rarity and overlapping features.
- Gene fusions are established diagnostic markers in various STS subtypes.
- Accurate classification is crucial for effective treatment strategies.
Purpose of the Study:
- To establish and validate a custom RNA sequencing panel for detecting gene fusions in STS.
- To assess the diagnostic performance of the RNA panel in clinical samples.
- To evaluate the panel's utility in classifying STS subtypes and aiding diagnosis.
Main Methods:
- Development and analytical validation of a custom RNA sequencing panel.
- Testing the panel on 145 formalin-fixed, paraffin-embedded (FFPE) STS patient samples.
- Comparison of RNA panel results with morphology and immunohistochemistry.
Main Results:
- The RNA panel identified 64 gene fusions in STS.
- Excellent analytical accuracy: 100% sensitivity, 93.33% specificity.
- Detected fusions in 40% of clinical samples (58/145), including challenging cases.
Conclusions:
- The RNA fusion panel accurately detects characteristic gene fusions in STS.
- It enhances STS subtype classification, especially when morphology is ambiguous.
- The panel shows significant potential as a supplementary tool for precise STS diagnosis.
